Breast Cancer Clinical Trial

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Summary

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.

View Full Description

Full Description

Study consists of three arms, Arm A is a Phase Ib/II study of TT-00420 tablet monotherapy, Arm B is a Phase Ib/II study of TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) and Arm C is a PK run-in study of TT-00420 tablet.

Arm A: TT-00420 Tablet Monotherapy Phase Ib will enroll patients with preferred indications including metastatic cholangiocarcinoma, HER2-negative breast cancer including TNBC, bladder cancer, small cell lung cancer, prostate cancer, thyroid cancer, sarcoma, gastric cancer, gallbladder cancer and other advanced solid tumors to receive TT-00420 monotherapy. Based on preliminary efficacy results, Phase II will enroll additional patients in select indications to evaluate the efficacy of TT-00420 monotherapy.

Arm B: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) Arm B will enroll patients with metastatic HER2-negative breast cancers, including triple-negative breast cancer (TNBC). Phase Ib will be a dose escalation study of TT-00420 in combination with nab-paclitaxel, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Phase II will enroll additional patients with metastatic HER2-negative breast cancers to further evaluate the efficacy of the combination regimen.

Arm C: PK Run-in Study of TT-00420 Tablet Arm C will enroll patients with preferred indications including cholangiocarcinoma, TNBC/HER2- negative breast cancer, prostate cancer, sarcoma, hepatocellular carcinoma (HCC), bladder cancer, small cell lung cancer, thyroid cancer, gastric cancer, gallbladder cancer and other advanced solid tumors to receive TT-00420 monotherapy administered as once daily (q.d.) or twice daily (b.i.d.).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

≥ 18 years of age
Histopathological or cytologically documented locally advanced or metastatic solid tumors who have no available standard therapeutic treatment options
At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Adequate organ function confirmed at screening and within 10 days of initiating treatment, as evidenced by:

Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
Hemoglobin (Hgb) ≥ 8 g/dl
Platelets (plt) ≥ 75 x 10^9/L
AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
Total bilirubin ≤ 1.5 x ULN
Calculated creatinine clearance ≥ 50 mL/min (Cockcroft Gault formula)
Negative pregnancy test within 72 hours before starting study treatment in all premenopausal women and women < 12 months after the onset of menopause
Must agree to take sufficient contraceptive methods to avoid pregnancy during the study and until at least 6 months after ceasing study treatment
Able to sign informed consent and comply with the protocol

Exclusion Criteria:

Women who are pregnant or lactating
Women of child-bearing potential (WOCBP) who do not use adequate birth control
Patients with any hematologic malignancy, including leukemia (any form), lymphoma, and multiple myeloma
Patients with a history of primary central nervous system tumors or carcinomatous meningitis.

Patients with the following mood disorders as judged by the Investigator or a psychiatrist:

Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia; a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
≥ CTCAE grade 3 anxiety

Impaired cardiac function or significant diseases, including but not limited to any of the following:

left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)
Congenital long QT syndrome
QTcF ≥ 480 msec on screening ECG
Unstable angina pectoris ≤ 3 months prior to starting study drug
Acute myocardial infarction ≤ 3 months prior to starting study drug

Patients with:

unresolved diarrhea ≥ CTCAE grade 2, or
impairment of gastrointestinal (GI) function, or
GI disease that may significantly alter the absorption of TT-00420
Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertension, uncontrolled hypertriglyceridemia, or active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
Patients who have received chemotherapy, targeted therapy, or immunotherapy ≤ 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have been treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 4 weeks prior to starting study drug.
Patients who are currently receiving treatment with therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants
Patients who have received systemic corticosteroids ≤ 2 weeks prior to starting study drug or who have not recovered from the side effects of such treatment.
Patients who are currently receiving treatment with strong CYP3A inhibitors or inducers ≤ 2 weeks prior to starting study drug.
Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled)
Known history of active infection with Hepatitis B or Hepatitis C
Has received a live-virus vaccination within 30 days of planned first dose
Inability to swallow or tolerate oral medication
Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

203

Study ID:

NCT04742959

Recruitment Status:

Completed

Sponsor:

TransThera Sciences (Nanjing), Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States
The University of Chicago
Chicago Illinois, 60637, United States
Rutgers Cancer Institute
New Brunswick New Jersey, 08901, United States
Gabrail Cancer Center Research
Canton Ohio, 44718, United States
UT Southwestern Medical Center
Dallas Texas, 75390, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

203

Study ID:

NCT04742959

Recruitment Status:

Completed

Sponsor:


TransThera Sciences (Nanjing), Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.